New study results strengthen hormone therapy, cancer link

Share this article:

Results from a large national study may have put the nail in the coffin of hormone replacement therapy (HRT) treatments, the Associated Press reported Saturday.

The Women's Health Initiative (WHI) study, a 15-year research program designed to address the most frequent causes of health problems and death in postmenopausal women, found that women taking estrogen and progestin pills for even a couple of years faced a greater risk of cancer, the AP reported from the San Antonio Breast Cancer Symposium. Wyeth's Prempro, an estrogen/progestin combination drug, is still FDA approved for severe menopausal symptoms.

After going off the treatments, however, women can expect cancer and other risks to diminish quickly, returning to normal levels in roughly two years. The study's leader, Rowan Chlebowski, told the AP that sharpens the previous message about HRTs: that they should only be used at the lowest doses and for the shortest amount of time possible.

Initial results from the study can be found at the WHI website. In a related story, Sen. Chuck Grassley requested documents relating to Wyeth's publishing practices with regards to Prempro. 

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?